Biopharmaceutical company developing transformative therapies for rare metabolic diseases, focusing on hyperinsulinism.
About
Rezolute is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases. Their primary focus is on hyperinsulinism-related hypoglycemia and diabetic retinal disease. The company's lead candidate, ersodetug, is an antibody therapy targeting insulin receptor signaling to reduce the clinical impact of excess insulin.
Pricing
View pricing page ↗Tags
Total Employees
5
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Rezolute do?
Rezolute is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases. Their primary focus is on hyperinsulinism-related hypoglycemia and diabetic retinal disease. The company's lead candidate, ersodetug, is an antibody therapy targeting insulin receptor signaling to reduce the clinical impact of excess insulin.
How much funding has Rezolute raised?
Rezolute has raised a total of $220M in funding. The most recent round on record is Offering.
Where is Rezolute headquartered?
Rezolute is headquartered in Redwood City, United States.
When was Rezolute founded?
Rezolute was founded in 2012.
What industry does Rezolute operate in?
Rezolute operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Rare Diseases.
How many employees does Rezolute have?
Rezolute has approximately 5 people on record.